A Phase 1/2 interventional study of NRTX-1001 in Epilepsy, Temporal Lobe, sponsored by Neurona Therapeutics. Recruiting at 17 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-01-07.
Sponsored by Neurona Therapeutics (part of UCB S.A.) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Epilepsy, Temporal Lobe with a site in United States — 10 open to participants now, 10 under way, none of them phase 3. Epilepsy, Temporal Lobe · United States.
Among the 30 studies in Epilepsy, Temporal Lobe with a site in United States, this one is the 10th largest by planned enrollment of the 19 interventional ones that give a count, is one of 3 that started in 2024, is the only one in phase 1/2, and was the 27th registered.
65 studies on the registry are indexed under Epilepsy, Temporal Lobe; 25 are open to participants now.
Browse Epilepsy, Temporal Lobe studies →10 of the 30 studies in Epilepsy, Temporal Lobe with a site in United States are open now. Recruiting first, the newest first:
Duke University · Sites in United States
Ages 18–70
University of California, Davis · Sites in United States
Ages 18–55 · Healthy volunteers
Nitin Tandon · Sites in United States
Ages 18–65
University of Southern California · Sites in United States
Ages 18–65
University of Pennsylvania · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 19 Epilepsy, Temporal Lobe studies recruiting now, 6 (32%) set no upper age limit and 9 (47%) stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 3 · Phase 3 1 · Phase 4 2
First in 1997; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 10 is below the median of 30 across 41 interventional studies indexed under Epilepsy, Temporal Lobe.
Median enrollment 10 across the 19 interventional studies, 50 across the 11 observational. Of the 18 that completed or were terminated, 6 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 30 have an industry lead sponsor. The 10 most frequent:
This study is registered under Neurona Therapeutics, one of the names counted as UCB S.A.. Under that name alone:
Neurona Therapeutics is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
UCB S.A. has 1 study filed under Epilepsy, Temporal Lobe — fewer than ten, so there is no comparison to draw.
3 of the studies in Epilepsy, Temporal Lobe with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02151175BrainSonix Inc.Low-intensity Focused Ultrasound Pulsation (LIFUP) for Treatment of Temporal Lobe Epilepsy | 2026-11 |
| NCT04649008University of PennsylvaniaLocalizing Epileptic Networks Using MRI and iEEG | 2027-02-28 |
| NCT06422923Neurona TherapeuticsA Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Mesial Temporal Lobe Epilepsy (MTLE) | 2027-06-15 |
Add all 3 to your calendar (.ics) → With an account.
Among the 30 studies in Epilepsy, Temporal Lobe with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multicenter, single arm, open label clinical trial that is designed to test the safety and preliminary efficacy of single administration inhibitory nerve cells called interneurons (NRTX-1001), into both temporal lobes of subjects with drug-resistant bilateral mesial temporal lobe epilepsy.
This is a multicenter, single arm, open-label study of NRTX-1001 in subjects with drug-resistant bilateral MTLE, with the objective of evaluating safety and preliminary efficacy in reducing seizure frequency. The subjects will undergo a single stereotactic CT or MRI-guided intracerebral administration of human interneurons into both temporal lobe regions of the brain. NRTX-1001 secretes the inhibitory neurotransmitter gamma-aminobutyric acid (GABA), which is intended to suppress the onset and spread of the seizures. Safety, tolerability, and effects on epilepsy disease symptoms will be assessed at approximately quarterly intervals for 2 years after the administration of NRTX-1001. After the two-year period, subjects will be followed with quarterly phone calls and annual visits in years 3 through 15.
Key Inclusion Criteria:
Either
bilateral temporal hypometabolism on 18-Flourodeoxyglucose Positron Emission Tomography (FDG PET) (assessed by visual assessment, comparing temporal regions to frontal/parietal lobe neocortex). In this case, ictal EEG recordings must also include intracranial confirmation.
or
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This is an open-label study of the bilateral intrahippocampal administration of NRTX-1001 in a single dose cohort of up to 10 subjects with drug-resistant bilateral MTLE.
Biological: NRTX-1001
Biological: NRTX-1001 is an inhibitory neural cell therapy investigational product. It is derived from a human stem cell line that has been converted into high-purity inhibitory interneurons that produce GABA. NRTX-1001 is intended to persist long-term and not require repeated administration.
Also known as: GABA-secreting interneurons
Incidence of Serious Adverse Events at end of month 12
Time frame: 12 months after treatment
Change in frequency of clinical seizures
Seizure frequency change during months 7-12, compared to frequency of clinical seizures in the 6-month baseline period.
Time frame: 12 months after treatment
Not enrolling at this site.
Plan to share: No
Started Nov 2024 (actual). Primary completion is estimated for Jun 2027, 31 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.